Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
Sponsor: Revolution Medicines, Inc.
Summary
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.
Official title: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
430
Start Date
2026-08-14
Completion Date
2031-02
Last Updated
2026-08-20
Healthy Volunteers
No
Conditions
Interventions
zoldonrasib
oral tablets
Placebo
oral tablets
pembrolizumab
IV infusion or Subcutaneous injection
pemetrexed + cisplatin /carboplatin
IV infusion of either pemetrexed + cisplatin or pemetrexed + carboplatin
Locations (1)
Florida Clinical Trials Group, LLC
Plantation, Florida, United States